News and Trends 25 Mar 2025 AbbVie and Genmab: Can a legal battle break a billion-dollar bond? …technology related to antibody-drug conjugates (ADCs). Genmab has rejected the claims and said it will defend itself, insisting the dispute will not impact its ongoing collaborations with AbbVie. But it’s… March 25, 2025 - 5 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 19 Sep 2023 Five biotech companies taking Los Angeles by storm …clinical candidate is vudalimab, which is currently in ongoing phase 2 clinical studies in metastatic castration-resistant prostate cancer and gynecologic tumors. The drug is a bispecific antibody that simultaneously targets… September 19, 2023 - 6 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 22 Feb 2022 Fast Stroke Treatments in the Works with TargED’s €39M Series A …Microlyse is a fusion protein drug combining an antibody fragment with a fragment of a clot-busting enzyme. The antibody part of the drug seeks out a protein target found in… February 22, 2022 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 31 Aug 2022 Researchers identify possible target for type of sporadic ALS …cells. When a synthetic antibody designed specifically to recognize HERV-K ENV was added as well to those neurons, the toxic effects were reduced. These findings together suggest that the improper… August 31, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Feb 2020 Adrenomed’s Antibody Drug Scores Hit in Phase II Septic Shock Trial German biotech Adrenomed reports that its first-in-class antibody drug adrecizumab was well-tolerated by septic shock patients and met its primary goal in a phase II trial. The company says it… February 24, 2020 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
In Depth 13 Jun 2023 Abeta-targeting antibodies pave the way for Alzheimer’s disease vaccines …treatment of Alzheimer’s disease In September 2022, the monoclonal antibody lecanemab, which targets a toxic species of Abeta protein, slowed cognitive decline in early Alzheimer’s disease by approximately 30% in… June 13, 2023 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jan 2020 Update: Chinese Pharma Enlists Synaffix’s ADC Technology for Second Drug …treatment based on antibody-drug conjugate technology from the Dutch company Synaffix. Synaffix develops technology to produce antibody-drug conjugates, commonly known as ADCs, which are antibodies with toxic chemotherapy drugs attached…. January 7, 2020 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 25 Oct 2018 Mastering the Competitive World of Immuno-oncology …of the antibody field and started his first company, 4-Antibody, in 2004. Before a successful sale to Agenus in 2014, the company developed therapeutic antibodies for a range of different… October 25, 2018 - 5 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 15 Dec 2022 Solve Therapeutics launches to tackle cancer …reviewing other potential in-licensing opportunities as well as performing in-house antibody discovery research. The company’s focus is on the development of novel mAbs, antibody drug conjugates incorporating next-generation linker and… December 15, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 13 Sep 2017 A Swedish-Spanish Team Takes on a New Immuno-Oncology Target …cells and can promote the survival, expansion and activity of these immune cells specialized in fighting cancer. Alligator Bioscience already has two antibody candidates in its pipeline that target… September 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2022 Trial for drug targeting cancerous tumors begins in China …(July 15). It is the thirteenth innovative oncology drug candidate discovered in-house by HUTCHMED and it is the company’s second large molecule drug candidate to enter clinical studies. The investigational… July 18, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
In Depth 10 Jun 2024 ASCO 2024: The latest advances in oncology clinical trials …care from chemotherapy to novel targeted therapies. At ASCO 2024, AbbVie’s antibody drug conjugate (ADC) platform was revealed, as the drugs are being developed to target solid tumors. A few… June 10, 2024 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email